anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To provide a hair dye composition which enables color development of a stabilized finishing color immediately after dyeing the hair in hair dyeing with the use of henna.SOLUTION: The hair dye composition is prepared by incorporating 0.0075-0.015 pts.wt. titanium dioxide powder on the surface of which calcium phosphate fine particles and silk fine particles have been adsorbed into 100 pts.wt. henna powder. The amount of the calcium phosphate fine particles is set at 0.1-25 pts.wt. based on 100 pts.wt. of the titanium dioxide and the amount of the silk fine particles is set at 0.1-2.5 pts.wt. based on 100 pts.wt. of the titanium dioxide. One or more of a natural indigo powder, a turmeric powder, a walnut shell grain, a tea leaf powder, a rose powder, a persimmon leaf powder, a coffee bean powder, a lemon peel powder, and an HC dye powder are further incorporated in this hair dye composition.
Background and Objectives: Frailty in older adults is associated with adverse health outcomes. This study aimed to analyze the frailty status of community-dwelling older adults in Taiwan using the Kihon Checklist (KCL) and explore associations with demographic, physiological, and functional factors. Materials and Methods: In this cross-sectional study, 278 community-dwelling older adults were classified as robust, prefrail, or frail based on their KCL scores. Participants underwent physical fitness assessments including muscle strength and endurance tests, walking speed tests, and flexibility tests. One-way ANOVA and logistic regression analyses were used to examine differences and associations between frailty status and physical fitness indicators. Results: 36% of participants were robust, 47.1% prefrail, and 16.9% frail. The robust group significantly outperformed the prefrail and frail groups in the 30 s sit-to-stand test, 2.44 m sit-to-walk test, and walking speed (p < 0.001). The 2.44 m sit-to-walk test was a significant predictor of prefrailty (OR = 1.18, 95% CI = 1.02-1.36) after adjusting for other physical fitness indicators. Conclusions: Lower limb functional capacity, particularly in the 2.44 m sit-to-walk test, was significantly associated with pre-frailty among community-dwelling older adults in Taiwan. Early screening, the classification of frailty by the Kihon Checklist, and targeted interventions focusing on lower limb strength, endurance, and mobility are crucial for preventing and delaying frailty progression in older populations.
BACKGROUND: Trisomy of the short arm of chromosome 9 (9p) is the fourth most common chromosomopathy. It is a partial or complete autosomal structural anomaly of the short arm of chromosome 9. It is generally caused by a reciprocal parental translocation between chromosome 9 and another autosome; spontaneous genetic alteration (de novo) is rare. It presents great phenotypic variability due to the variable size of the chromosome fragment involved.
CLINICAL CASE: We present the case of a patient diagnosed with trisomy of the short arm of chromosome 9 with a karyotype with a chromosomal complement 46,XX,add(9)(p24), interpreted as an additional chromosome fragment on chromosome 9p. A microarray study was carried out, which reported that the 9p24.3-p13.1 region is found in triple dose, which corresponds to a partial trisomy 9p or Rethoré syndrome, which is a low prevalence entity, with an expressiveness and variable prognosis. In the present case, the finding of a murmur and diagnosis of pulmonary valve stenosis was the initial approach; The heart disease described in our patient has not been reported in the literature as part of the clinical picture, meaning that it was not an initial diagnostic suspicion.
CONCLUSION: Despite having described an already defined phenotype, other clinical data that are not documented should be considered, and when new clinical evidence is found, report it and thereby expand the phenotype for a timely diagnosis.
Participants will receive two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT to the target index lesion(s) should be completed within 30 days after simulation after completion of the 2nd infusion of Radium (Ra-223) dichloride. Specific dose constraints, dosing schedules, and management of SBRT to multiple sites will be at the discretion of the treating Radiation oncologist. The goal is to complete simulation and SBRT within 30 days. Only active or progressive disease is to be treated at the discretion of the treating investigator.
IPI-145 given at dose of 75 mg orally twice daily for 4 weeks. Courses repeated about every 4 weeks (range 4-6 weeks).
Some recent data have suggested a beneficial effect of GnRHa administered in the luteal phase on the outcome of assisted reproduction techniques. In those studies, the dose and administration time of GnRHa are inconsistent. Single administration on third day after embryo transfer and multiple dose injection during luteal phase are the most common way. The GnRHa included Triptorelin 0.1mg, Leuprorelin 1mg and Buserelin 600ug et al. The exact underlying mechanism is still not clear, although it has been hypothesized that GnRH agonist either supports the corpus luteum function by inducing LH secretion by the pituitary gonadotrophin cells or stimulates the endometrium GnRH receptors . Tesarik et al.postulated a direct effect of GnRH agonist on the embryo, evidenced by increased β-HCG secretion.

Currently, available data suggest that inadvertent administration of a GnRH agonist during a conception cycle is not accompanied by an increased risk of birth defects. On the basis of the currently strong available evidence, it appears that GnRH agonist supplementation during luteal phase significantly improve the outcome of ART treatment. Most of the former researches focused only on fresh embryo transfer in IVF/ICSI cycles. In one prospective controlled study, a single dose of Triptorelin 0.1mg was administrated 6 days after ICSI in oocyte donor cycles and the implantation rate was improved significantly.GnRH agonist administration at the time of implantation enhances embryo developmental potential, probably by a direct effect on the embryo.
<P>PROBLEM TO BE SOLVED: To provide a coronavirus disinfectant having effective antiseptic effect on coronavirus and having high safety on human.  <P>SOLUTION: A composition containing at least one kind of compound selected from hinokithiol and its salt and derivative as a main component and containing at least one pharmaceutically acceptable carrier or vehicle is used. For example, 0.5% hinokitiol is uniformly mixed with 97.5% alcohol, 1% purified water and 1% dipropyleneglycol to provide a liquid agent and the liquid agent is packed into a bottle, etc. and is used as a disinfectant for coronavirus. The liquid agent is packed into a spray container and is sprayed into the interior, articles, the air, mask, etc and is used for prevention, etc., of infection.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Subjects will receive a single dose of of 1-3x10\^7 cells/m\^2 lentiviral transduced huCART-meso cells on day 0 following a minimum 1 week washout from standard care chemotherapy. This initial intrahepatic infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart.
Therapy is usually started with one 2.5 mg tablet of Mecamylamine HCl twice a day. This initial dosage should be modified by increments of one 2.5 mg tablet at intervals of not less than 2 days until the desired blood pressure response occurs (the criterion being a dosage just under that which causes signs of mild postural hypotension).

The average total daily dosage of Mecamylamine HCl is 25 mg, usually in three divided doses. However, as little as 2.5 mg daily may be sufficient to control hypertension in some patients. A range of two to four or even more doses may be required in severe cases when smooth control is difficult to obtain. In severe or urgent cases, larger increments at smaller intervals may be needed. Partial tolerance may develop in certain patients, requiring an increase in the daily dosage of Mecamylamine HCl.

Administration of Mecamylamine HCl after meals may cause a more gradual absorption and smoother control of excessively high blood pressure. The timing of doses in relation to meals should be consistent. Since the blood pressure response to antihypertensive drugs is increased in the early morning, the larger dose should be given at noontime and perhaps in the evening. The morning dose, as a rule, should be relatively small and in some instances may even be omitted.

The initial regulation of dosage should be determined by blood pressure readings in the erect position at the time of maximal effect of the drug, as well as by other signs and symptoms of orthostatic hypotension.

The effective maintenance dosage should be regulated by blood pressure readings in the erect position and by limitation of dosage to that which causes slight faintness or dizziness in this position. If the patient or a relative can use a sphygmomanometer, instructions may be given to reduce or omit a dose if readings fall below a designated level or if faintness or lightheadedness occurs. However, no change should be instituted without the knowledge of the physician.

Close supervision and education of the patient, as well as critical adjustment of dosage, are essential to successful therapy. 

Other Antihypertensive Agents

When Mecamylamine HCl is given with other antihypertensive drugs, the dosage of these other agents, as well as that of Mecamylamine HCl, should be reduced to avoid excessive hypotension. However, thiazides should be continued in their usual dosage, while that of Mecamylamine HCl is decreased by at least 50 percent.
Current practice guidelines stipulate that 65% of all prevalent ESRD patients should receive HD through some sort of arterio-venous fistula (AVF). An AVF is a subcutaneous, permanent vascular access created surgically by connecting a vein with an artery and is the preferred mode of access due to lower rates of infection or thrombosis compared to prosthetic grafts or tunneled lines. An AVF is mature if it can sustain high quality HD. However, rates of primary failure (the inability of an AVF to sustain HD) are high, ranging from 40-70%. Traditional coronary risk factors such as hypertension, hypercholesterolemia, and diabetes mellitus, have limited ability to allow surgeons to predict which AVFs will mature.

One possible explanation involves vascular remodeling, the structural changes which occur in a blood vessel in response to hemodynamic stimuli. The endothelial, lying at the interface of the vessel wall and flowing blood, is a "biosensor", responding to changes in blood flow and pressure. It initiates a complex biological response including cellular proliferation and migration, matrix degradation, and cellular apoptosis. This longitudinal, observational study hypothesizes that endothelial function is a critical modulator of AVF maturation. Specifically, that patients with inflammation will have impaired endothelial function and demonstrate less significant remodeling than others.
Premature Closure of Fetal Ductus Arteriosus   
Avoid use of NSAIDs, including NALFON, in pregnant women at about 30 weeks gestation and later. NSAIDs, including NALFON, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age. 

Oligohydramnios/Neonatal Renal Impairment   
Use of NSAIDs, including NALFON, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. 

Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit NALFON use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if NALFON treatment extends beyond 48 hours. Discontinue NALFON if oligohydramnios occurs and follow up according to clinical practice [ see Use in Specific Populations ( 8.1) ].
Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
High mortality and morbidity rates associated with ST-elevation myocardial infarction (STEMI) and post-STEMI heart failure (HF) necessitate proper risk stratification for coronary artery disease (CAD). A prediction model that combines specificity and convenience is highly required. This study aimed to design a monocyte-based gene assay for predicting STEMI and post-STEMI HF. A total of 1,956 monocyte expression profiles and corresponding clinical data were integrated from multiple sources. Meta-results were obtained through the weighted gene co-expression network analysis (WGCNA) and differential analysis to identify characteristic genes for STEMI. Machine learning models based on the decision tree (DT), support vector machine (SVM), and random forest (RF) algorithms were trained and validated. Five genes overlapped and were subjected to the model proposal. The discriminative performance of the DT model outperformed the other two methods. The established four-gene panel (HLA-J, CFP, STX11, and NFYC) could discriminate STEMI and HF with an area under the curve (AUC) of 0.86 or above. In the gene set enrichment analysis (GSEA), several cardiac pathogenesis pathways and cardiovascular disorder signatures showed statistically significant, concordant differences between subjects with high and low expression levels of the four-gene panel, affirming the validity of the established model. In conclusion, we have developed and validated a model that offers the hope for accurately predicting the risk of STEMI and HF, leading to optimal risk stratification and personalized management of CAD, thereby improving individual outcomes.
PROBLEM TO BE SOLVED: To provide a medicine audit device and a program capable of easily confirming that medicine is included in an instruction.SOLUTION: A medicine audit device includes: a display part; display control means; a storage part; a reading device; identification means; determination means; and notification means. The display control means allows the display part to display an instruction as the list of designated medicine. The storage part stores the medicine instructed by the instruction. The reading device reads an identifier stored in a radio tag disposed in the storage part by radio communication. The identification means identifies the medicine by reading the identifier stored in the radio tag of the medicine stored in the storage part via the reading device. The determination means determines whether or not the medicine identified by the identification means is the medicine instructed by the instruction. The notification means notifies whether or not the medicine is instructed by the instruction from the determination means.
956,558. Pharmaceutical granules. GLAXO GROUP Ltd. Sept. 2, 1960 [Sept. 10, 1959], No. 30964/59. Heading A5B. [Also in Divisions A2, B5 and F4] Powdery materials such as pharmaceutical products which may contain a binding agent, e.g. magnesium stearate, are granulated or agglomerated by first forming them into individual masses of contiguous particles which are then subjected to steam treatment and thereafter drying to form coherent granules or agglomerates, the steam-treatment and drying steps being carried out in a manner such that there is no substantial relative movement between the contiguous particles of each individual mass. The steam with which the steam treatment is carried out is free from droplets larger than 0.1 mm. in diameter, and the drying step is conducted using hot air and/or radiant heat. Individual masses of contiguous particles of material deposited by a granulator 18 on a plastic or plastic-covered belt 8 are treated in a lagged chamber 19 with steam issuing from a number of tubes 68, are dried during their passage through a lagged chamber 20 by an electric radiant heater 79 and a current of hot air from a tunnel 80, and the dried granules or agglomerates are directed by a spring-tensioned scraper 93 into a quickly moving stream of cold air in the duct 88 by which they are conveyed to a cyclone for collection. The steam chamber 19 has a steam-heated jacket 65 and a detachable inspection plate 92 heated by steam pipes 91. The material may be forcibly fed into duct 88 by a worm to subdivide the granules or agglomerates into smaller masses. The material may, for example, remain in the steam chamber for 4-11 seconds and in the drying chamber for 5-16 seconds, the average temperature in the drying chamber being 175- 190‹ C. and the temperature of the heated air flow to the drying chamber being 100-110‹ C. Specification 810,813 is referred to.
The present invention provides virus vectors of the family Paramyxoviridae in which the transcription start (S) sequence has been modified so as to modify the expression of genes located downstream thereof, a method for producing the vectors, and uses thereof. By measuring the transcription initiation efficiency of the S sequence of each gene carried by Sendai viruses (SeV), it was clarified that the S sequence of F gene has a significantly lower ability to promote transcription than the other three S sequences. When the S sequence of the F gene of wild type Sendai virus was substituted by the S sequence of the P/M/HN gene-type showing a high transcription initiation efficiency, the F gene of the resultant Sendai virus mutant and genes located downstream thereof show elevated expression levels. It was also revealed that this mutant proliferates more quickly than the wild type. The vectors of this invention are useful in elevating the expression of foreign genes and producing pharmaceutical compositions and vaccines. Furthermore, by lowering virus gene expression from virus vectors, it is possible to suppress transcription and/or replication and reduce cytotoxicity of the vector genome.
FIELD: food industry, medicine. SUBSTANCE: invention relates to compositions used for administration of iodine-containing substances in body. Invention proposes iodine-containing composition comprising mixtures of crystals of sodium chloride with laminarin-containing product in pharmacologically acceptable doses. Laminarin, sugar laminaria or products of its processing are used laminarin-containing product in the dose 0.01-0.1% of total composition weight. Invention provides the exception of possibility of iodine overdosing. Stability of new salt is improved in storage, it shows enhanced anticaking indices, in part, it can be stored without loss of properties for 7 and more years. EFFECT: improved properties of composition. 4 cl, 2 tbl, 3 ex
The invention discloses a method for precisely predicting a treatment scheme of a localized liver cancer patient by artificial intelligence, and relates to the technical field of artificial intelligence prediction. The invention constructs a survival model of liver cancer patients adopting hepatic arterial chemoembolization (TACE) and hepatectomy (LR) by adopting an artificial intelligence algorithm mode by using a plurality of continuity indexes including tumor burden, liver function state, other basic data and common laboratory examination indexes. The treatment scheme is also input into the model as independent parameters for the first time, and a prognosis model integrating LR and TACE can be obtained, namely, the prognosis survival condition of the same patient adopting LR and TACE can be predicted at the same time. The concept is also put forward for the first time, and an integrated prognosis model of different treatment schemes is designed and developed. A web page designing the PTA model is developed and a web page related local name is applied (www.pta4hcc.com). The invention uses Artificial Intelligence (AI) to simulate and distribute the survival results of patients with different treatments, and has good effect.
AIMS: Single-lead electrocardiograms (ECGs) can be recorded using widely available devices such as smartwatches and handheld ECG recorders. Such devices have been approved for atrial fibrillation (AF) detection. However, little evidence exists on the reliability of single-lead ECG interpretation. We aimed to assess the level of agreement on detection of AF by independent cardiologists interpreting single-lead ECGs and to identify factors influencing agreement.
METHODS AND RESULTS: In a population-based AF screening study, adults aged ≥65 years old recorded four single-lead ECGs per day for 1-4 weeks using a handheld ECG recorder. Electrocardiograms showing signs of possible AF were identified by a nurse, aided by an automated algorithm. These were reviewed by two independent cardiologists who assigned participant- and ECG-level diagnoses. Inter-rater reliability of AF diagnosis was calculated using linear weighted Cohen's kappa (κw). Out of 2141 participants and 162 515 ECGs, only 1843 ECGs from 185 participants were reviewed by both cardiologists. Agreement was moderate: κw = 0.48 (95% confidence interval, 0.37-0.58) at participant level and κw = 0.58 (0.53-0.62) at ECG level. At participant level, agreement was associated with the number of adequate-quality ECGs recorded, with higher agreement in participants who recorded at least 67 adequate-quality ECGs. At ECG level, agreement was associated with ECG quality and whether ECGs exhibited algorithm-identified possible AF.
CONCLUSION: Inter-rater reliability of AF diagnosis from single-lead ECGs was found to be moderate in older adults. Strategies to improve reliability might include participant and cardiologist training and designing AF detection programmes to obtain sufficient ECGs for reliable diagnoses.
PURPOSE:The titled composition, containing an oyster meat extract as an active ingredient, capable of extinguishing symptoms, e.g. delusion, auditory hallucina tion, thinking disturbance, etc., in several weeks and useful as a remedy for schizophrenia, particularly hebephrenic schizophrenia, etc. CONSTITUTION:A composition for treating schizophrenia containing an oyster meat extract consisting of, e.g. hot water extract of oyster meat, preferably precipitates obtained by fractionating further the above-mentioned extract with an alcohol or enzymic hydrolyzate of the oyster meat extract, etc., as an active ingredient. The oyster meat extract is preferably an extract containing an abundant zinc chelate compound having particularly the following properties; (1) <=5,000 molecular weight mesured by gel filtration analysis using Sephadex, (2) containing taurine and Zn as principal constituent ingredients, (3) positive to ninhydrin reaction, (4) soluble in water and (5) UV absorption; the maximum absorption at 270-280nm. The effect on paranoid schizophrenia is remarkably increased by using a chlropromazine based pharmaceutical together.